- Home
- ARVN vs TRAX Comparison
ARVN vs TRAX Comparison
Compare ARVN & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | TRAX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 623.9M |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ARVN | TRAX |
|---|---|---|
| Price | $7.85 | $36.48 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | ★ 705.4K | 535.7K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.97 | $15.69 |
| 52 Week High | $14.22 | $49.91 |
Technical Indicators
Market Signals| Indicator | ARVN | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 33.46 | 40.77 |
| Support Level | N/A | $35.11 |
| Resistance Level | $9.69 | $48.94 |
| Average True Range (ATR) | 0.32 | 2.85 |
| MACD | -0.11 | -0.38 |
| Stochastic Oscillator | 0.58 | 10.17 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.